At a glance
ClinicalIndex Comparison RecordN/ACompleted· 300 enrolled
Drug / intervention
PCV13 PAC studybiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHILDREN AGED 5 MONTHS TO ≤60 MONTHS AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
In Brief
A clinical study evaluating PCV13 PAC study for Immunogenicity, Vaccine. Completed, enrolled 300 participants across 1 site.
Detailed Summary
This is a PAC study after PCV13 launch in China. Based on recommendation from China Agency, Pfizer was required to conduct a descriptive immunogenicity study to measure the antibody levels at the time of disease onset.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunogenicity, Vaccine
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartAug 2019
Primary CompletionDec 2021
First PostedMay 2022
TodayJul 2026
First PostedMay 12, 2022
Enrollment StartAug 15, 2019
Primary CompletionDec 14, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.1 years ago
Interventions
PCV13 PAC studybiological
To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.